Dolutegravir-Related Neurological Adverse Events : A Case Report of Successful Management with Therapeutic Drug Monitoring
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.org..
OBJECTIVE: Dolutegravir (DTG), a highly effective second-generation HIV integrase inhibitor with high genetic barrier to resistance, has shown excellent tolerability and safety profiles in clinical trials. However, some patients may experience neurological or psychiatric adverse effects leading to DTG discontinuation.
CASE REPORT: This report describes a case of 29-year-old woman who developed neurological adverse events after starting the DTG-based antiretroviral therapy. Serum DTG concentrations were supratherapeutic which has required a dosing interval adjustment. The findings of this case report suggest that Therapeutic Drug Monitoring might be useful in individuals expressing unusual DTG pharmacokinetics.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2018 |
---|---|
Erschienen: |
2018 |
Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
---|---|
Enthalten in: |
Current drug safety - 13(2018), 1 vom: 01., Seite 69-71 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Parant, Francois [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 20.09.2018 Date Revised 09.12.2020 published: Print Citation Status MEDLINE |
---|
doi: |
10.2174/1574886313666180116124046 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM280074743 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM280074743 | ||
003 | DE-627 | ||
005 | 20231225024514.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2018 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.2174/1574886313666180116124046 |2 doi | |
028 | 5 | 2 | |a pubmed24n0933.xml |
035 | |a (DE-627)NLM280074743 | ||
035 | |a (NLM)29345598 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Parant, Francois |e verfasserin |4 aut | |
245 | 1 | 0 | |a Dolutegravir-Related Neurological Adverse Events |b A Case Report of Successful Management with Therapeutic Drug Monitoring |
264 | 1 | |c 2018 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 20.09.2018 | ||
500 | |a Date Revised 09.12.2020 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.org. | ||
520 | |a OBJECTIVE: Dolutegravir (DTG), a highly effective second-generation HIV integrase inhibitor with high genetic barrier to resistance, has shown excellent tolerability and safety profiles in clinical trials. However, some patients may experience neurological or psychiatric adverse effects leading to DTG discontinuation | ||
520 | |a CASE REPORT: This report describes a case of 29-year-old woman who developed neurological adverse events after starting the DTG-based antiretroviral therapy. Serum DTG concentrations were supratherapeutic which has required a dosing interval adjustment. The findings of this case report suggest that Therapeutic Drug Monitoring might be useful in individuals expressing unusual DTG pharmacokinetics | ||
650 | 4 | |a Case Reports | |
650 | 4 | |a Journal Article | |
650 | 4 | |a Dolutegravir | |
650 | 4 | |a INSTI. | |
650 | 4 | |a adverse events | |
650 | 4 | |a antiretroviral | |
650 | 4 | |a pharmacokinetics | |
650 | 4 | |a therapeutic drug monitoring | |
650 | 7 | |a HIV Integrase Inhibitors |2 NLM | |
650 | 7 | |a Heterocyclic Compounds, 3-Ring |2 NLM | |
650 | 7 | |a Oxazines |2 NLM | |
650 | 7 | |a Piperazines |2 NLM | |
650 | 7 | |a Pyridones |2 NLM | |
650 | 7 | |a dolutegravir |2 NLM | |
650 | 7 | |a DKO1W9H7M1 |2 NLM | |
700 | 1 | |a Miailhes, Patrick |e verfasserin |4 aut | |
700 | 1 | |a Brunel, Florence |e verfasserin |4 aut | |
700 | 1 | |a Gagnieu, Marie-Claude |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Current drug safety |d 2006 |g 13(2018), 1 vom: 01., Seite 69-71 |w (DE-627)NLM181475790 |x 2212-3911 |7 nnns |
773 | 1 | 8 | |g volume:13 |g year:2018 |g number:1 |g day:01 |g pages:69-71 |
856 | 4 | 0 | |u http://dx.doi.org/10.2174/1574886313666180116124046 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 13 |j 2018 |e 1 |b 01 |h 69-71 |